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Background and objective
Immunostimulating interstitial laser thermotherapy by Clinical Laserthermia Systems AB (imILT CLS ) [1] is a local laser ablation treatment that makes use of the potential immunological effect induced by laser ablation [2] [3] [4] [5] [6] [7] [8] [9] . It is intended for controlled local tumor ablation, with a follow-on systemic immune activation against any remaining cancer cells. The procedure has its origins in the laser-induced interstitial thermotherapy (LITT) procedure and is based on a proprietary and patented technique to optimize the immunological effect. The treatment is minimally invasive as it requires the insertion of only two needles: a temperature sensor and an optical fiber.
During an imILT CLS treatment session, laser light is delivered to the tissue by means of an optical probe, inducing a temperature gradient within the tissue [10] . The aim is to increase the tissue temperature at the border of the desired lesion to a treatment temperature of 46°C (warm-up period) and to maintain this temperature for 30 min (treatment period). The tumor is most viable and metabolically active in the tumor border at which point the temperature is regulated. Both the treatment temperature and exposure time are selected to ensure complete cell necrosis in the targeted tissue [11] and it has been shown to produce an immunologically driven anti-tumor response [3] . Similar effects have been shown in other types of interstitial thermo therapies such as radiofrequency ablation [12] .
Throughout the treatment period, a feedback control adjusts the laser energy according to the temperature recorded by the master probe inserted at the edge of the target lesion. Consequently, four different components need to be designed for this system: (1) a laser source including a thermometry system and treatment feedback control, (2) an optical probe, (3) an introducer for positioning of the fiber and (4) a temperature sensor.
Accurate control of the tissue temperature using a feedback system that adjusts the light dose according to the temperature measured in the tissue is essential. This allows precise ablation without harming the surrounding tissue, especially in areas that are hard to access. The availability of suitable optical probes is limited by the duration of an imILT CLS treatment that imposes harsher working conditions on the probe than in the regular LITT treatments. The current state of the art for LITT makes use of neodymium-yttrium-aluminum-garnet (Nd:YAG) lasers or Nd: laser diodes combined with either large core, bare-end quartz fibers, water-cooled probes or fiber bundles, cooled or not cooled [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] .
This publication focuses on the first development steps in designing an appropriate non-cooled optical probe for imILT CLS in combination with a suitable laser source. The strategy of Clinical Laserthermia Systems AB (CLS) for design and development, shown in Figure 1 , is to set up a collaboration network with other companies and institutions to get the best expertise in each field. Ideally the product should be the result of a synergy between CLS's know-how about medical applications gained by long experience both in clinical and pre-clinical studies of the application, laser technology, thermometry, expertise in regulatory affairs, and the design support and production technology provided by its industry partners.
Design input and product specifications 2.1 Laser source
The laser selected for use is required to optimize the penetration depth and the energy distribution in the tissue and at the same time enhance the system usability and safety and to minimize costs, dimensions and user's learning curve. On this basis, the laser source chosen is an InGaAsP laser diode that emits light at a wavelength of 1064 nm and a power of up to 25 W continuous wave. The particular wavelength of 1064 nm is in the so-called 'optical window' of 600-1200 nm range, allowing deep light penetration in the tissue. For this reason this wavelength is commonly used for laser ablation procedures [13] . The power level was a tradeoff between the limitations imposed by the risk of carbonization, and maximization of the laser power to minimize the treatment time and the risk of treatment failure due to a heat sink effect, especially in highly vascularized tissues.
Optical probe
The probe design is based on requirements specified by customers. These are: -Predictability and reproducibility of the lesion size to ensure efficacy and safety; this requirement implies that the same lesion can be achieved in various tissue types and that its shape is easily adaptable and equally predictable in all directions (i.e. spherical). -Minimal invasiveness to minimize tissue damage, and injury and stress to the patient, i.e. small outer diameter of the probe ( < 3 mm) is mandatory. -Good visibility with imaging techniques to allow easy positioning of the active tip and of the temperature sensor in the tissue. -Good mechanical stability, i.e. the tip of the probe or its insertion aid (e.g. introducer) should be sharp and steerable to allow easy penetration and positioning in the target tissue with minimum harm and discomfort for the patient. -Low costs for production, which is subsequently reflected in the end product price on the market. -Good connectability, i.e. long and flexible connection to the main unit (e.g. optical fiber or cable) is needed.
The most relevant requirement is the ability to achieve large and predictable lesions in all kinds of tissues. In order to configure such an optical probe, parameters such as tip design, materials and outer diameter need to be defined. According to these requirements, a non-cooled diffuser fiber was developed in three stages, as shown in Figure 2 and described as follows.
Cooled diffuser fiber
The starting point for the probe development was a cooled diffuser fiber with a 10 mm or 15 mm diffuser tip. Numerous diffusers, cooled and non-cooled, are available that Figure 2 : Development stages for the non-cooled diffuser fiber. The starting point for the probe development was a cooled diffuser fiber which had some limitations regarding large lesions in medium to highly vascularized tissues with only minimum risk for the patient. The next step was to integrate the diffuser technology used for a cooled diffuser solution and radial fiber tip design. This fusion of modalities led to the design of a non-cooled diffuser fiber -based on a technology provided by Laser-und Medizin-Technologie GmbH, Berlin (LMTB).
have been developed specifically for medical use, with diffusers ranging from 5 to 100 mm and a reduced outer diameter to avoid unnecessary and unacceptable tissue damage [14, 15, [18] [19] [20] [21] . Ultimately, a product, approved for clinical use in the United States, was tested to assess whether it was suitable for imILT CLS as this therapy requires long treatment times.
An extensive project was started in parallel that involved three different suppliers, including the Laserund Medizin-Technologie GmbH, Berlin (LMTB), to try to improve the design of the cooled diffuser fiber and to produce CLS's own product. Unfortunately CLS's own product did not reach the in vivo testing phase. Therefore the results are not included in this publication.
Radial fiber
In a second step, a totally different technical solution was implemented to overcome the problems encountered with the cooled diffuser: a radial fiber. A radial fiber is a fiber that emits light in a plane, approximately perpendicular to its axis, due to the conical polishing of its tip (Figure 3) . It is equipped with a protective cap that improves its thermal and mechanical stability. This fiber is usually used for endovascular applications [22] .
Non-cooled diffuser fiber
The next step was to merge the diffuser technology used for the cooled diffuser project and the radial fiber tip design in order to increase the power that can be applied to the tumor without risk for the patient. This led to the design of a non-cooled diffuser fiber (Figure 4) , a fiber that emits light along the diffuser length, approximately perpendicular to its axis. It is also equipped with a protective cap that improves its thermal and mechanical stability.
Testing
Validation methods
Firstly, the intensity profile of the delivered light was assessed by submerging the different optical probes in an Intralipid ® solution [500 μl/l in phosphate-buffered saline (PBS)]. The different diffuser types were then tested (1) ex vivo in a bovine cardiac muscle model, and (2) in vivo in porcine skeletal muscle and liver models. During these tests, the temperature was continuously monitored by means of two temperature probes. The master probe was placed at the border of the lesion to be achieved, and a multi-point (MP) temperature probe was used to measure the temperature within the lesion borders to determine the temperature gradient induced in the tissue. The performance of the fibers was evaluated in terms of usability and with regard to lesion size and carbonization episodes. Furthermore, technical failures were recorded and assessed for severity and possible safety risks.
Ex vivo validation
The ex vivo validation was performed in bovine cardiac muscle. This model was chosen because it is a reproducible tissue model that provides a suitable basis for planning in vivo tests, both in moderately and in highly perfused tissues. The tissue was submerged in PBS at pH 7.4 and maintained at a constant temperature of 37°C in a water bath during the entire procedure. The positioning of the optical fiber and the temperature sensors was performed using a template with one central hole that fitted the fiber, and additional holes positioned 5-25 mm apart at 5 mm intervals. The master temperature probe was inserted into the tissue at a given distance from the laser fiber (see Table 1 ). The additional MP temperature probe was inserted at a distance of 5 mm from the fiber and its insertion depth was adjusted so that the temperatures along the fiber and up to 5 mm deeper than the diffusing tip of the fiber could be monitored. The depth was guaranteed using markings made prior to insertion. The parallel positioning was guided by the template.
The laser power was set to the maximum allowed power for each fiber and was determined during a separate set of experiments. The parallel position of the master probe together with the set power level is reported in Table 1 . The lesion size was evaluated directly after the treatment was finished. In these tests the effect of low temperature ablation is not visible therefore only the coagulation zone was evaluated.
In vivo validation
The in vivo validation was performed in a porcine survival model both in moderately perfused tissue (skeletal muscle) and in highly perfused tissue (liver). Experiments were performed according to protocols approved by the Animal Ethics Committee in Lund, Sweden.
The setup used was the same as for the ex vivo tests. The laser power was set to a specific level for each fiber and tissue type combination, corresponding to the maximum allowed for the given combination which was determined in a separate set of experiments. The parallel position of the master probe together with the set power level is shown in Table 2 .
Experience from the previous test series showed that the ex vivo model is usually more challenging than the in vivo model due to the lack of cooling effect from the vascularization in the ex vivo model. Therefore the power level used during ex vivo tests was used as a reference for tests in highly vascularized tissues. The power recommended for low and medium vascularized tissue is generally higher.
The animals that were treated in vivo in skeletal muscle tissue were euthanized 3-4 days after treatment to allow the effect of the low temperature heating (necrosis outside the coagulation volume) to be assessed by lesion evaluation. The animals that were treated in vivo in the liver were euthanized directly after the last treatment to minimize risks from infection due to open surgery. For this reason it was not possible to observe the effect of mild heating since this is only visible after at least 3 days after treatment.
The tests performed with the cooled diffuser fiber were performed with a special power protocol designed to Lesions were limited by the size of the muscle used as the model. minimize carbonization probability for this fiber type. The laser power was set to 10 W after 8 min of treatment. Tables 1 and 2 present the results of the tests performed ex vivo and in vivo, respectively. The data is presented in terms of the average maximum lesion size that can be obtained safely using different applicators. An exception is made for the non-cooled diffuser since the test results are limited to the size of the muscle treated during the tests. The difference in the lesion size reported in the ex vivo and in vivo tests are due to the low temperature at which the ablation was performed. The damage induced by low temperature heating can be appreciated only in survival model because coagulation does not occur on the edges of the necrotized volume.
First results
Results using the cooled diffuser fiber, designed with a plastic cooling catheter, showed that it was unsuitable for imILT CLS treatment. It was not possible to safely achieve large lesions in medium to highly vascularized tissues without potential risk for the patient, either in terms of failed treatment or risk of contamination due to fiber rupture. Table 2 does not present any results for lesions induced with this applicator in liver because it was not possible to obtain lesions without tissue carbonization. The 10 mm diffuser used at lower power levels was more suitable for highly vascularized tissue than the 15 mm diffuser because the magnitude of the carbonization was less but, from the safety aspect, the improvement was not significant enough.
Different laser probes have been studied in literature. With the non-cooled ones with a non-plastic design, the radial fiber could withstand relatively high energy rates during a prolonged period of time if compared to a bare-end fiber [10] . After investigation, redesign and extensive tests, it was decided that a radial fiber was a suitable product for CLS application. Using this design all the problems caused by use of the cooled plastic design could be overcome. It was possible to obtain reproducible and approximately spherical lesions. However, the limitations in lesion size and the range of tissue that could be treated remained the same. It was possible to obtain lesions of approximate 20 mm in highly vascularized tissue and approximately 30 mm in medium to low vascularized tissue. Table 2 shows a lesion size of 15 mm in liver, which is a 5 mm smaller diameter than expected, because low temperature necrosis was not entirely visible using our evaluation methods. The product was released onto the market as it was considered to be safe and acceptable, but more research work was required.
In the last step of the development, the non-cooled diffuser fiber design allowed us to obtain large lesions even in highly vascularized tissues. The diffuser length for this fiber was limited to 10-15 mm to be able to achieve spherical lesions, within the limits of the geometrical construction of the diffuser. The maximum lesion obtained in the limited test series performed with this fiber has shown that lesions in excess of 40 mm can be obtained. The values reported in Table 2 are not conclusive about the full potential of this fiber because the lesions were limited by the size of the muscle treated and further testing is required.
However, the ex vivo tests indicate that the non-cooled diffuser is suitable for inducing significantly larger lesions in highly vascularized tissues with a reduced risk for the patient. Due to the tip design, it is possible to use higher power levels before carbonization occurs. Even if carbonization should occur, the choice of materials ensures that no toxic or foreign particles are released into the body. Table 3 shows a comparison between the three different development stages and user requirements. The first results have shown that the non-cooled diffuser fiber is the most promising solution so far in terms of maximization of the lesion size and the range of tissues that can be Table 3 : The different development stages are plotted against to the user requirements. The result of the collaboration is a design output -the non-cooled diffuser -that satisfies the user's needs.
User requirement
Cooled diffuser Radial fiber Non-cooled diffuser treated safely. On the other hand, the main restriction, i.e. the geometrical shape limiting the minimum lesion size, makes it unsuitable for achieving small lesions. In these cases, the use of a radial fiber is not only safer but more convenient.
Conclusion
One promising technical solution for increasing achievable lesion sizes and therefore increasing the immunological benefits of the treatment, is the use of a diffuser that can withstand high power levels for the prolonged periods of time that are required during an imILT CLS procedure. The network of collaborations that have been set up by CLS have allowed the design and development of a custom-made product that combines state-of-the-art technology and the niche 'know-how' to fulfill user needs and market requirements ( Table 3 ). The design output -a non-cooled diffuser fiber -satisfies the user's needs, although additional testing is required to examine the full potential of this product.
